Intarcia Therapeutics
Intarcia Therapeutics is a Hayward, California-based, privately held biopharmaceutical company founded in 1997 that develops therapies for chronic, long-term diseases, funded by 20+ rounds totaling over $1.7 billion from healthcare-focused institutional investors.
- Company typePrivate
- Founded1997
- HeadquartersHayward, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Intarcia Therapeutics does
Intarcia Therapeutics is a privately held, clinical-stage biopharmaceutical company founded in 1997 and headquartered in Hayward, California, that develops therapies for diseases requiring long-term chronic treatment. The firm has built a 251-500 employee organization and has financed its operations through 20+ disclosed funding rounds since 2000, accumulating in excess of $1.7 billion from a syndicate of healthcare-focused institutional investors including NEA, Venrock, RA Capital Management, Baillie Gifford, Fidelity, Foresite Capital, and the Bill & Melinda Gates Foundation. Leadership indicates a regulated pharmaceutical operating model, with dedicated roles for Global Regulatory Affairs and Quality, Regulatory Compliance, Chemistry, and a Chief Medical Officer who also heads Regulatory Affairs globally.
The business model is a pre-commercial therapeutics developer, with all disclosed financial metrics showing operating losses and no product revenue line. Revenue mechanics, pricing, distribution channels, and customer segments are not disclosed in the provided sources, and the company's own domain (intarcia.com) is currently listed for sale on the Atom marketplace rather than pointing to an active corporate site, which together with the absence of any disclosed post-2019 funding or product milestones limits visibility on current operating status. The single disclosed corporate transaction in the record is the September 2015 acquisition of Phoundry Pharmaceuticals for an undisclosed amount, used to expand the development pipeline.
Intarcia Therapeutics firmographics
Firmographics- Name
- Intarcia Therapeutics
- Website
- https://intarcia.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Intarcia Therapeutics is a Hayward, California-based, privately held biopharmaceutical company founded in 1997 that develops therapies for chronic, long-term diseases, funded by 20+ rounds totaling over $1.7 billion from healthcare-focused institutional investors.
- Ownership category
- akta.pro rank
Intarcia Therapeutics industry classification
Industry- NAICS
- Other Ambulatory Health Care Services (6219)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Gastroenterology Specialty Pharmaceuticals (HLAIACAE)
- akta.pro secondary industry
- Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)
Keywords
Where Intarcia Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Hayward
- HQ country
- United States
- HQ region
- North America
Markets served
Intarcia Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Intarcia Therapeutics product offering
Product offeringCore offering
Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment, centered on a proprietary long-acting implantable drug delivery system designed to provide continuous, steady-state dosing of medication over extended periods (months to a year or more) for patients with chronic conditions such as type 2 diabetes. The company combines drug formulation science with a miniaturized subcutaneous delivery device to reduce dosing frequency and improve adherence in chronic disease management.
Product overview
No product or service information for Intarcia Therapeutics was found in the provided source data. The available sources contained only a domain marketplace listing for the sale of the intarcia.com domain name, and an unrelated market report about refrigerator display cases in Spain.
Differentiator
Problem solved
Functional benefit
Products and services
- Long-acting implantable therapy for chronic diseases
Companies that use Intarcia Therapeutics
Customer profileIdeal customer profiles1 record
Intarcia Therapeutics technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Intarcia Therapeutics partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights4 records
Intarcia Therapeutics competitors and assessment
Company assessmentBroad incumbents
- AstraZeneca: Acquired Amylin and markets Bydureon BCise (exenatide once-weekly). Directly relevant incumbent in the same molecule and indication Intarcia targeted.
- Insulet Corporation: Omnipod tubeless insulin pump for diabetes. Comparable as a durable device-based diabetes therapy platform serving the same end-prescribers and patients.
- Novo Nordisk: Global GLP-1 leader (Ozempic, Rybelsus, Victoza) for type 2 diabetes and obesity. Sets the competitive standard Intarcia's long-acting delivery would need to displace.
- Eli Lilly: Major diabetes franchise (Trulicity, Mounjaro, Zepbound) and broad metabolic-disease pipeline. Defines the GLP-1 competitive landscape Intarcia would need to penetrate.
- Dexcom: Leading continuous glucose monitoring (CGM) franchise. Adjacent but relevant — defines the connected diabetes device ecosystem into which Intarcia's delivery platform would integrate.
Emerging players
- Dance Biopharm: Developed inhaled insulin (Dance 501) using a proprietary delivery platform. Comparable niche chronic-disease device-pharma hybrid targeting type 2 diabetes.
- Tandem Diabetes Care: Insulin pump and connected diabetes management devices (t:slim, t:slim X2). Comparable as an innovative device-led diabetes therapy company targeting improved adherence and outcomes.
Direct peers
- Amylin Pharmaceuticals: Developed sustained-release exenatide (Bydureon), the same GLP-1 molecule Intarcia's ITCA 650 sought to deliver via an implantable pump. Acquired by AstraZeneca in 2012; directly comparable molecule, indication, and delivery-format ambitions.
- MannKind Corporation: Developer of Afrezza (inhaled insulin) and the Technosphere drug-delivery platform. Closest pure-play peer in chronic-disease drug delivery technology with a proprietary device-based platform.
- Valeritas: Developed V-Go, a wearable basal insulin delivery device for type 2 diabetes. Comparable in targeting adherence challenges in type 2 diabetes via an alternative delivery format.
Market position
Strengths4 records
Weaknesses2 records
Competitive moat3 records
Key risks5 records
Key highlights7 records
Customer concentration
Intarcia Therapeutics social profiles
Digital presenceIntarcia Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Intarcia Therapeutics leadership team
Management profileNumber of profiles
Profiles7 records
Intarcia Therapeutics funding detail
Funding detailFunding overview
Funding rounds22 records
Investors28 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Intarcia Therapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Intarcia Therapeutics
What does Intarcia Therapeutics do?
Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment, centered on a proprietary long-acting implantable drug delivery system designed to provide continuous, steady-state dosing of medication over extended periods (months to a year or more) for patients with chronic conditions such as type 2 diabetes. The company combines drug formulation science with a miniaturized subcutaneous delivery device to reduce dosing frequency and improve adherence in chronic disease management.
Is Intarcia Therapeutics a public or private company?
Intarcia Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Intarcia Therapeutics founded?
Intarcia Therapeutics was founded in 1997. It employs 251 to 500 people.
Where is Intarcia Therapeutics based?
Intarcia Therapeutics is headquartered in Hayward, United States, in the North America region.
Who are Intarcia Therapeutics's main competitors?
Broad incumbents on record are AstraZeneca, Insulet Corporation, Novo Nordisk, Eli Lilly and Dexcom. Emerging players are Dance Biopharm and Tandem Diabetes Care. Direct peers are Amylin Pharmaceuticals, MannKind Corporation and Valeritas.
Does Intarcia Therapeutics have an API?
No public API is recorded for Intarcia Therapeutics.
What industry is Intarcia Therapeutics in?
Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals, with a secondary code of HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators). Its NAICS code is 6219 and its SIC code is 2834.